Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Tribal Patent Deal Could Impact Generic Drug Market

Jan Wolfe  |  September 12, 2017

(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

Anne Harding  |  September 12, 2017

NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…

Medication Adherence for Osteoporosis Prevention

Michele B. Kaufman, PharmD, BCGP  |  September 12, 2017

In a new study, patients taking denosumab had greater treatment adherence over two years than patients on alendronate and other anti-osteoporosis agents…

Visit the New RISE Dashboard!

From the College  |  September 11, 2017

Current participants of the Rheumatology Informatics System for Effectiveness (RISE) Registry can now access the RISE dashboard and receive an estimated MIPS score for the 2017 performance year. (Note: This score is only an estimation and cannot guarantee the type of future payment adjustment; only CMS can determine penalties and bonuses.) If you are a current user,…

Steroids May Increase Infection Risk in Patients with IgA Nephropathy

Lara C. Pullen, PhD  |  September 11, 2017

Treatment with oral methylprednisolone may be associated with an increased risk of serious adverse events, specifically infection, in patients with IgA nephropathy. Despite the five-times higher risk, study results also showed a three-times lower risk of kidney failure for the treatment group…

Rheumatology & The Gender Pay Gap

Richard Quinn  |  September 8, 2017

On average, male rheumatologists earn 16.2%—or $38,493—more than female rheumatologists. Although the data seem jarring, a closer look at it is needed to truly understand the pay gap…

U.S. Senator Reveals Results of Opioid Inquiry into Insys

Nate Raymond  |  September 7, 2017

BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…

High Prevalence of Kingella Kingae in Children with Joint Infections

Anne Harding  |  September 7, 2017

NEW YORK (Reuters Health)—Oropharyngeal carriage of Kingella kingae is strongly associated with osteoarticular infection in young children, a case-control study done from Canada and Switzerland shows. “Most of the kids who have osteoarticular infection with Kingella kingae will also have it in their throat, so if we do a throat swab, we can identify it…

FDA Update: Biosiomilar to Adalimumab Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  September 6, 2017

The FDA has approved adalimumab-adbm, a biosimilar, to treat multiple chronic inflammatory diseases…

ACR Opposes UnitedHealthCare’s Move to End Consultation Reimbursement

Carina Stanton  |  September 6, 2017

Effective for claims with dates of service on or after Oct. 1, 2017, UnitedHealthCare (UHC) plans to no longer reimburse consultation services represented by CPT codes 99241–99245 and 99251–99255. In lieu of a consultation services procedure code, UHC says it will “reimburse the appropriate evaluation and management (E/M) procedure code which describes the office visit,…

  • « Previous Page
  • 1
  • …
  • 185
  • 186
  • 187
  • 188
  • 189
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences